HECTD2 and hepatocellular carcinoma: Similarly, lactylation of HECT domain E3 ubiquitin protein ligase 2 (HECTD2) has been shown to limit the response of HCC to lenvatinib by facilitating the degradation of Kelch-like ECH-associated protein 1 (KEAP1) and activating the KEAP1/NRF2 signaling pathway, which initiates an antioxidative response [127].